While 2017 was a banner year, several headwinds shaped investment strategies: Pharm Exec's Top 50 Companies 2017 | PharmExec
: Rose nearly 700% following a lucrative licensing deal with Novartis for its antibody gevokizumab. pharma stocks to buy 2017
: Gained over 700% after positive Phase 2 data for its epilepsy treatment, ganaxolone. While 2017 was a banner year, several headwinds
: Maintained its lead in prescription sales and remained a "Strong Buy" due to its robust clinical pipeline and steady dividend. While 2017 was a banner year